Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers

Aim Proteinuria and estimated glomerular filtration rate (eGFR) predict progression of renal impairment in type 2 diabetic nephropathy (DN) but are they still predictive when these patients are treated with angiotensin receptor blockers (ARB)? We investigated whether residual (after ≥3 months of ARB...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nephrology (Carlton, Vic.) Vic.), 2013-07, Vol.18 (7), p.516-524
Hauptverfasser:	Ivory, Sara E, Packham, David K, Reutens, Anne T, Wolfe, Rory, Rohde, Richard D, Lewis, Julia, Atkins, Robert C
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Albuminuria - diagnosis Albuminuria - drug therapy Albuminuria - etiology Albuminuria - physiopathology angiotensin Angiotensin II Type 1 Receptor Blockers - therapeutic use Biomarkers - blood Biomarkers - urine Creatinine - blood Creatinine - urine Diabetes Mellitus, Type 2 - complications Diabetic Nephropathies - diagnosis Diabetic Nephropathies - drug therapy Diabetic Nephropathies - etiology Diabetic Nephropathies - physiopathology diabetic nephropathy Disease Progression Double-Blind Method Female glomerular filtration rate (GFR) Glomerular Filtration Rate - drug effects Humans Kaplan-Meier Estimate Kidney - drug effects Kidney - physiopathology Male Middle Aged Proportional Hazards Models proteinuria renal failure Risk Assessment Risk Factors Serum Albumin - metabolism Serum Albumin, Human Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aim Proteinuria and estimated glomerular filtration rate (eGFR) predict progression of renal impairment in type 2 diabetic nephropathy (DN) but are they still predictive when these patients are treated with angiotensin receptor blockers (ARB)? We investigated whether residual (after ≥3 months of ARB treatment) urinary protein/creatinine ratio (rPCR) or urinary albumin/creatinine ratio (rACR) and residual eGFR (reGFR), predict subsequent progression. Methods One thousand, two hundred and forty‐five patients with type 2 DN from two international multi‐center studies were analysed. Cross classification of rPCR, rACR with reGFR (rPCR:
ISSN:	1320-5358 1440-1797
DOI:	10.1111/nep.12053